A detailed history of Saturna Capital Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Saturna Capital Corp holds 115,368 shares of ABBV stock, worth $22.5 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
115,368
Previous 115,368 -0.0%
Holding current value
$22.5 Million
Previous $21 Million 5.81%
% of portfolio
0.27%
Previous 0.29%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$159.82 - $182.1 $95,892 - $109,260
600 Added 0.52%
115,368 $21 Million
Q4 2023

Feb 06, 2024

BUY
$137.6 - $154.97 $178,880 - $201,461
1,300 Added 1.15%
114,768 $17.8 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $3,339 - $3,866
25 Added 0.02%
113,468 $16.9 Million
Q2 2023

Aug 04, 2023

BUY
$132.51 - $164.9 $245,143 - $305,065
1,850 Added 1.66%
113,443 $15.3 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $6.44 Million - $7.42 Million
-44,548 Reduced 28.53%
111,593 $17.8 Million
Q4 2022

Feb 09, 2023

SELL
$138.31 - $165.87 $17,288 - $20,733
-125 Reduced 0.08%
156,141 $25.2 Million
Q3 2022

Nov 10, 2022

SELL
$134.21 - $153.93 $5.33 Million - $6.11 Million
-39,705 Reduced 20.26%
156,266 $21 Million
Q2 2022

Aug 12, 2022

SELL
$137.62 - $174.96 $23.4 Million - $29.7 Million
-169,930 Reduced 46.44%
195,971 $30 Million
Q1 2022

May 10, 2022

BUY
$131.98 - $163.75 $52,791 - $65,500
400 Added 0.11%
365,901 $59.3 Million
Q4 2021

Feb 09, 2022

SELL
$107.43 - $135.93 $17,833 - $22,564
-166 Reduced 0.05%
365,501 $49.8 Million
Q2 2021

Aug 11, 2021

SELL
$105.21 - $117.21 $21,252 - $23,676
-202 Reduced 0.06%
365,667 $41.2 Million
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $3,154 - $4,221
43 Added 0.01%
365,869 $35.9 Million
Q1 2020

May 14, 2020

SELL
$64.5 - $97.79 $41,925 - $63,563
-650 Reduced 0.18%
365,826 $27.9 Million
Q4 2019

Feb 13, 2020

SELL
$72.13 - $90.25 $288,520 - $361,000
-4,000 Reduced 1.08%
366,476 $32.4 Million
Q3 2019

Nov 14, 2019

SELL
$62.98 - $75.72 $1.95 Million - $2.35 Million
-31,000 Reduced 7.72%
370,476 $28.1 Million
Q2 2019

Jul 31, 2019

SELL
$65.7 - $83.98 $335,201 - $428,465
-5,102 Reduced 1.25%
401,476 $29.2 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $77 - $90
1 Added 0.0%
406,578 $32.8 Million
Q4 2018

Feb 08, 2019

SELL
$77.85 - $96.01 $77,850 - $96,010
-1,000 Reduced 0.25%
406,577 $37.5 Million
Q2 2018

Aug 02, 2018

BUY
$89.78 - $106.23 $2.63 Million - $3.11 Million
29,299 Added 7.75%
407,577 $37.8 Million
Q1 2018

May 10, 2018

SELL
$92.01 - $123.21 $55,206 - $73,926
-600 Reduced 0.16%
378,278 $35.8 Million
Q4 2017

Feb 06, 2018

BUY
$89.56 - $98.21 $53,915 - $59,122
602 Added 0.16%
378,878 $36.6 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $13,969 - $17,844
200 Added 0.05%
378,276 $33.6 Million
Q2 2017

Aug 14, 2017

BUY
N/A
378,076
378,076 $27.4 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $345B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Saturna Capital Corp Portfolio

Follow Saturna Capital Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Saturna Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Saturna Capital Corp with notifications on news.